Integra Lifesciences Holdings (IART) Cash & Current Investments (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Cash & Current Investments data on file, last reported at $265.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 2.86% year-over-year to $265.5 million; the trailing twelve-month figure through Mar 2026 stood at $265.5 million (down 2.86% YoY), and the FY2025 full-year result was $263.7 million, down 3.59% from the prior year.
• Cash & Current Investments grew to $265.5 million in Q1 2026, from $263.7 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $663.1 million in Q1 2024 to a low of $253.6 million in Q2 2025.
• A 5-year average of $344.6 million and a median of $296.9 million in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments soared 115.74% in 2024 and sank 58.78% in 2025, its largest moves.
• Tracing IART's Cash & Current Investments over 5 years: stood at $456.7 million in 2022, then slumped by 32.31% to $309.1 million in 2023, then declined by 11.49% to $273.6 million in 2024, then retreated by 3.59% to $263.7 million in 2025, then rose by 0.66% to $265.5 million in 2026.
• Business Quant data shows IART's Cash & Current Investments at $265.5 million in Q1 2026, $263.7 million in Q4 2025, and $267.9 million in Q3 2025.